Safety of Once-Daily (qd) Budesonide and Formoterol Administered via One Pressurized Metered-Dose Inhaler (pMDI) in Adults and Adolescents With Asthma Previously Stable With Twice-Daily (bid) Budesonide/Formoterol pMDI

No clinically significant findings were observed in clinical laboratory values (including serum glucose and potassium), vital signs (heart rate, blood pressure), or physical examinations for any budesonide/formoterol group versus budesonide.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2008-02, Vol.121 (2), p.S153-S153
Main Authors: LaForce, C, Kerwin, E.M, Oppenheimer, J.J, Miller, C.J, Vervaet, P, O'Dowd, L, Goldman, M
Format: Article
Language:English
Subjects:
Allergy and Immunology
Drug dosages
Medical treatment
Physical examinations
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No clinically significant findings were observed in clinical laboratory values (including serum glucose and potassium), vital signs (heart rate, blood pressure), or physical examinations for any budesonide/formoterol group versus budesonide.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2007.12.562